EGA: Shaping the 2020 regulatory landscape for patient needs

A total of 61 regulators from 25 countries made progress in improving the generic and biosimilar medicines regulatory landscape for patient needs at the 15th Regulatory and Scientific Affairs Conference organized by the European Generic and Biosimilar medicines Association (EGA), the trade group stated.

The EMA/HMA Strategy 2020, complemented by the CMDh 2020 Strategy Paper, will pursue operational excellence in the EU Regulatory Network and engagement in international regulatory platforms which will ultimately deliver greater value to public health.

The generic and biosimilar medicines industries presented a number of regulatory improvements in the EGA Regulatory Efficiency report in support of the 2020 strategies.